MAIA (MAIA Biotechnology, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MAIA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Vlad Vitoc | Chief Executive Officer | Buy | — | — |
| 2026-09-14 | Ramiro Guerrero | Director | Buy | — | — |
| 2026-09-01 | Ramiro Guerrero | Director | Buy | — | — |
| 2026-08-26 | Ramiro Guerrero | Director | Buy | — | — |
| 2026-08-24 | Ramiro Guerrero | Director | Buy | — | — |
| 2026-07-02 | Cristian Luput | Director | A | — | — |
| 2026-07-02 | Ngar Yee Louie | Director | A | — | — |
| 2026-07-02 | Stan Smith | Director | A | — | — |
| 2026-07-02 | STEVEN M CHAOUKI | Director | A | — | — |
| 2026-07-02 | Jean-Manasse Theagene | Director | A | — | — |
| 2026-07-02 | Ramiro Guerrero | Director | A | — | — |
| 2026-06-02 | Vlad Vitoc | Chief Executive Officer | Buy | — | — |
| 2026-06-02 | Stan Smith | Director | Buy | — | — |
| 2026-06-02 | Sergei Gryaznov | Chief Scientific Officer | Buy | — | — |
| 2026-06-01 | Sergei Gryaznov | Chief Scientific Officer | A | — | — |
| 2026-06-01 | Vlad Vitoc | Chief Executive Officer | A | — | — |
| 2026-06-01 | Jeffrey C Himmelreich | Head of Finance | A | — | — |
| 2026-04-14 | Jeffrey C Himmelreich | Head of Finance | A | — | — |
| 2026-04-14 | Vlad Vitoc | Chief Executive Officer | A | — | — |
| 2026-04-14 | Sergei Gryaznov | Chief Scientific Officer | A | — | — |
| 2026-04-02 | Ramiro Guerrero | Director | A | — | — |
| 2026-04-02 | Cristian Luput | Director | A | — | — |
| 2026-04-02 | STEVEN M CHAOUKI | Director | A | — | — |
| 2026-04-02 | Jean-Manasse Theagene | Director | A | — | — |
| 2026-04-02 | Ngar Yee Louie | Director | A | — | — |
| 2026-04-02 | Stan Smith | Director | A | — | — |
| 2026-01-12 | Stan Smith | Director | MIXED | — | — |
| 2026-01-05 | Jean-Manasse Theagene | Director | A | — | — |
| 2026-01-05 | Stan Smith | Director | A | — | — |
| 2026-01-05 | STEVEN M CHAOUKI | Director | A | — | — |
| 2026-01-05 | Ngar Yee Louie | Director | A | — | — |
| 2026-01-05 | Cristian Luput | Director | A | — | — |
| 2026-01-05 | Ramiro Guerrero | Director | A | — | — |
| 2025-12-23 | STEVEN M CHAOUKI | Director | Buy | — | — |
| 2025-12-23 | Ngar Yee Louie | Director | Buy | — | — |
| 2025-12-23 | Stan Smith | Director | Buy | — | — |
| 2025-12-09 | Stan Smith | Director | Buy | — | — |
| 2025-12-04 | Vlad Vitoc | Chief Executive Officer | Buy | — | — |
| 2025-12-04 | Vlad Vitoc | Chief Executive Officer | Buy | — | — |
| 2025-12-01 | Cristian Luput | Director | Buy | — | — |
| 2025-12-01 | Stan Smith | Director | Buy | — | — |
| 2025-12-01 | Vlad Vitoc | Chief Executive Officer | Buy | — | — |
| 2025-11-28 | Cristian Luput | Director | Buy | — | — |
| 2025-11-28 | Vlad Vitoc | Chief Executive Officer | Buy | — | — |
| 2025-11-26 | Stan Smith | Director | Buy | — | — |
| 2025-11-25 | Vlad Vitoc | Chief Executive Officer | Buy | — | — |
| 2025-10-06 | Cristian Luput | Director | A | — | — |
| 2025-10-06 | Stan Smith | Director | A | — | — |
| 2025-10-06 | Ngar Yee Louie | Director | A | — | — |
| 2025-10-06 | Jean-Manasse Theagene | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 1,259,221 | — |
| — | Director | 1,248,888 | — |
| — | Director | 773,296 | — |
| — | Director | 419,483 | — |
| — | Director | 376,933 | — |
| — | Director | 151,873 | — |
| — | Chief Scientific Officer | 46,511 | — |
| — | Chief Medical Officer | 27,100 | — |
| — | Chief Financial Officer | 9,400 | — |
| — | Director | 4,580 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MAIA quote page; the site-wide leaderboard is on the insider transactions hub.